Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
McKinsey
Colorcon
Express Scripts

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Donepezil Hydrochloride; Memantine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status Development Center for Biotechnology, Taiwan Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status Program Office, National Science & Technology, Biotechnology & Pharmaceuticals Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status Taipei Veterans General Hospital, Taiwan Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00154635 ↗ Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease Unknown status National Taiwan University Hospital Phase 2 2005-09-01 A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of the sample size we could expect but a positive trend of the efficacy unless the effect size of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical investigation such as a phase III study should be carried out in an even larger scale. We also should be able to obtain valuable experience on the adverse effect of prolonged (24-week) use of Fo-ti.
NCT00181298 ↗ Memantine in Systemic Lupus Erythematosus Completed Forest Laboratories N/A 2006-03-01 Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor.
NCT00181298 ↗ Memantine in Systemic Lupus Erythematosus Completed Johns Hopkins University N/A 2006-03-01 Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor.
NCT00234637 ↗ Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment Completed Novartis Phase 4 2003-11-01 This is a prospective, multicenter, open-label study. Following screening and baseline assessments, eligible patients will be switched to rivastigmine and will enter the 16 week run-in rivastigmine treatment phase. After completion of assessments at the end of the run-in phase, patients who were not sufficiently stabilized on rivastigmine alone will receive add-on memantine to their rivastigmine treatment; patients who were stabilized on rivastigmine alone will have completed and be discontinued from the study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Donepezil Hydrochloride; Memantine Hydrochloride

Condition Name

Condition Name for Donepezil Hydrochloride; Memantine Hydrochloride
Intervention Trials
Alzheimer's Disease 10
Alzheimer Disease 4
Dementia 3
Mild Cognitive Impairment 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Donepezil Hydrochloride; Memantine Hydrochloride
Intervention Trials
Alzheimer Disease 18
Dementia 5
Cognitive Dysfunction 2
Aphasia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Donepezil Hydrochloride; Memantine Hydrochloride

Trials by Country

Trials by Country for Donepezil Hydrochloride; Memantine Hydrochloride
Location Trials
United States 93
Spain 6
Canada 5
France 4
United Kingdom 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Donepezil Hydrochloride; Memantine Hydrochloride
Location Trials
California 5
North Carolina 5
Massachusetts 5
Florida 5
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Donepezil Hydrochloride; Memantine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Donepezil Hydrochloride; Memantine Hydrochloride
Clinical Trial Phase Trials
Phase 4 9
Phase 3 5
Phase 2 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Donepezil Hydrochloride; Memantine Hydrochloride
Clinical Trial Phase Trials
Completed 17
Unknown status 3
Recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Donepezil Hydrochloride; Memantine Hydrochloride

Sponsor Name

Sponsor Name for Donepezil Hydrochloride; Memantine Hydrochloride
Sponsor Trials
Forest Laboratories 4
Johns Hopkins University 2
New York State Psychiatric Institute 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Donepezil Hydrochloride; Memantine Hydrochloride
Sponsor Trials
Other 27
Industry 14
U.S. Fed 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Colorcon
Baxter
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.